Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
ico-007 (1 trial)
ranibizumab (lucentis) (1 trial)
Edema (Phase 2)
Macular Edema (Phase 2)
Trials (1 total)
Trial APIs (2 total)